29 May 2025NewsAmericasRavi Srinivasan, JA Kemp

WATCH: Evergreening (or life cycle management patents—including polymorphs and patents arising from clinical trial data

Ravi Srinivasan of JA Kemp explores strategies for identifying, prosecuting, and defending follow-on patent applications after a therapeutic product enters the public domain. The session at LSPN covers patents based on clinical trial data and polymorphs of small molecule drugs.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
28 January 2026   The rise of fake online stores selling counterfeit pharmaceuticals is driving a surge in domain name disputes, forcing major brands to defend revenue and reputation.
Americas
27 January 2026   As quantum-enabled innovation accelerates, patentability will hinge on predictability, disclosure, and modality-specific claim drafting in an increasingly unforgiving enablement landscape, explain Ray Miller and Joseph Wolfe of DLA Piper
Americas
26 January 2026   The court found the board applied the wrong legal standard when evaluating Guardant Health’s obviousness challenge to a University of Washington DNA sequencing patent.